Gail Page

In October of 2018, Ms Page joined Turret Capital as a Venture Partner where she leverages her years of experience and network in the Diagnostics and Clinical Laboratory sectors.
This dovetails with her earlier work at Vineyard Investment Advisors, (2013-2018) which focused on partnering with entrepreneurs, businesses, and universities to transform their ideas into products and services.
Prior to this venture, Ms. Page served as the President / CEO of Vermillion, Inc. from Jan 2004 thru December 2012 and was a member of the board of directors.
Upon joining Vermillion in 2004 she inspired a pioneering spirit.
which repositioned the company to embrace the progressive nature of its pipeline, successfully raised over $100M in funding, developed and commercially launched the first FDA-cleared novel multiproteomic/MAAA blood test to aid in the diagnosis of ovarian cancer and engaged Quest Diagnostics as an equity and commercial partner.
Prior to serving Vermillion, she held executive positions at Laboratory Corporation of America and Luminex.
Ms Page is a member of the board of directors for the following companies: Chembio Diagnostics, NxPrenatal, Sword Diagnostics, and Valtari Diagnostics.
She has been recognized by Forbes Women and Business week for her work in the sector.
Most recently, she served as Interim CEO for Chembio and led a successful transition.
Ms. Page earned her degrees from Santa Fe Community College and the University of Florida.
In 2003 she completed an executive management program at the Kellogg School in Chicago.